Harvard Bioscience (HBIO)
Builds research tools for preclinical and cellular-and-molecular science.
$7.81
After hours−0.14 (−1.76%)
At close$7.95(−0.63%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 29.73% | 1.35M shares | |
|---|---|---|---|
| 34 holders · as of Jun 30, 2026 | |||
| Insiders | 33.01% | 1.50M shares | |
| 9 holders · as of Jun 12, 2026 | |||
| Other | 37.26% | 1.70M shares | |
| remainder | |||
4.55M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
34 holders · 1.35M shares · 4 new positions · 7 increased · 15 reduced · 6 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Weber Capital Management LLC /Adv | 310.9K | 6.83% | −9.2K | Aug 13, 2026 |
| Acadian Asset Management LLC | 179.6K | 3.95% | 0 | Aug 13, 2026 |
| Vanguard Capital Management LLC | 169.6K | 3.73% | +6.3K | Aug 13, 2026 |
| Corsair Capital Management, L.P. | 122.8K | 2.70% | −2.0K | Aug 14, 2026 |
| Two Sigma Investments, LP | 114.5K | 2.52% | +428 | Aug 14, 2026 |
| Renaissance Technologies LLC | 99.3K | 2.18% | −2.1K | Aug 13, 2026 |
| BlackRock, Inc. | 61.8K | 1.36% | −392 | Aug 7, 2026 |
| Geode Capital Management, LLC | 47.6K | 1.04% | −12.0K | Aug 12, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| William Sniderincl. BroadOak Capital Partners, LLC, BroadOak Fund VI, L.P. +1 more | 15.97% | 846.0K | 13D | Mar 23, 2026 |
| Weber Capital Management, LLC | 7.26% | 13G | May 8, 2025 | |
| Leviticus Partners LP | 6.50% | 293.7K | 13G | May 14, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Mar 16, 2026 | Mark T. Frostofficer: Chief Financial Officer | Purchase | 5,000 | $5.00 | 17,500 |
| Mar 16, 2026 | William Sniderdirector | Purchase | 12,525 | $4.99 | 23,525 |
| Mar 17, 2026 | William Sniderdirector | Purchase | 8,475 | $4.85 | 32,000 |
| Mar 17, 2026 | Stephen J. Denelskydirector | Purchase | 10,000 | $4.87 | 21,000 |
| Mar 16, 2026 | John D. Dukedirector, officer: Chief Executive Officer | Purchase | 5,000 | $5.01 | 105,000 |
House and Senate disclosures
Not reported.